Zero to a billion... A CDMO original - part 1

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with part 1 of our episode with Thomas Eldered, Executive Chairman at Flerie. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering: Where his entrepreneurial spark originated, and how they created a CMO (before that was even a thing) after several failed plans How did the timing of his first exit and having ‘cash during the crash’ fuel M&A to grow Recipharm into an international powerhouse? Why did he decide to go public? No one else in Sweden or in the CDMO space was getting an IPO A lifetime with Lars (his business partner) and the benefit of a partnership with aligned common interest Why he decided to sell Recipharm after 26 years and why leaving the company was the most difficult mental decision Thomas Eldered was co-founder of Recipharm AB in 1995, where he served as CEO from 2008 to 2021, growing Recipharm from a local Swedish pharmaceutical contract manufacturer to an international CDMO with more than 9000 employees in 10 countries. He also founded Flerie Invest AB in 2011, where he is currently Executive Chairman. Thomas is currently chairman of the board and a member of the board of several life science companies.  He holds a Master of Science in Industrial Engineering and Management from Linköping University. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.